Doc, perhaps 5-ALA was more extensively used to remove the GBM tumors of the last 108 patients and that may have been one of the reasons that at least 38.9% of that last cohort survived past 36 months whereas at most only 22.9% of the first 223 were as lucky. However, that most likely was not only the reason for almost doubling the percent of post 36 months survivors.
I tend to believe that NWBO intended to end up with a 2:1 ratio and were not so blatantly sloppy as to terminate this long trial with 2.34 times more Treatment than control patients. Over such a long enrollment period, NWBO had plenty of time to basically maintain a 2:1 ratio.
I therefore believe that for the first 300 patients a 2:1 ratio was maintained but most if not all of the last 32 patients were Treatment patients. There were about 83 Treatment patients and only 25 Control patients in that last group of 108 and that may be the main reason for the superior survival capacity of that last group.
Witness the German patient about to be enrolled during the late stages of the trial, who according to his wife was told by his physician that the trial was now closed but that he would most likely have only received the placebo. How did the physician know that unless he was told that the trial reached the maximum number of Treatment patients and/or if the trial were to continue, the rest of the patients were only going to receive the placebo. Perhaps at that point, it was ethical to inform the physicians that the trial was over but that their patients did not lose much because had the trial been extended, they would have only received the placebo.
AI
Market Data 
Markets 
